Clinical trials: Cardiomyopathy, Hypertrophic
Hypertrophic Cardiomyopathy (HCM)
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
- Trial name
- NCT06599229
- Testing
- myocardial contrast echo
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Hypertrophic Cardiomyopathy (HCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow…
- Trial name
- NCT07381894
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- University of Manchester
Cardiomyopathies, Myocarditis
The Heart Hive - Cardiomyopathy Study
This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.
- Trial name
- NCT04612296
- Testing
- Research genetic analysis
- Where
- United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- Imperial College London
HCM - Hypertrophic Cardiomyopathy
Observational Study for Patients With Hypertrophic Cardiomyopathy
Observational study on patients with hypertrophic cardiomyopathy aims to investigate the correlation between cardiac fibrosis, as indicated by cardiac magnetic resonance, and the prognosis, and further to explore biomarkers for…
- Trial name
- NCT04851652
- Testing
- No intervention nor exposure
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Guangdong Provincial People's Hospital
Hypertrophic Cardiomyopathy, Hearing Loss
Refining Information Technology Support for Genetics in Medicine
The clinical use of genetic testing is expanding and, as a result, the number of variants identified in patients is growing. Knowledge of the clinical impact of these variants improves over time.
- Conditions
- Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
- Trial name
- RISGIM (NCT01225978)
- Testing
- GeneInsight Clinic (GIC)
- Where
- 9 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic…
- Trial name
- NCT07263204
- Where
- China
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Obstructive Cardiomyopathy
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation.
- Trial name
- NCT06003478
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Xijing Hospital
Non-obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
- Trial name
- IMPROVE-HCM (NCT04826185)
- Testing
- IMB-1018972
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 67 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Hypertrophic Cardiomyopathy
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results Number of subjects: 100 (including 10% dropout rate) Performance and safety were verified by…
- Trial name
- ATP-HCM (NCT06873828)
- Testing
- ATP-C135, ATP-C75
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Congenital Heart Defect
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease
Genetically inherited heart diseases (familial cardiopathies) are conditions affecting the heart passed on to family members by abnormalities in genetic information.
- Trial name
- NCT00027196
- Where
- United States
- Volunteers
- 9,999,999 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Hypertrophic Cardiomyopathy
Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a…
- Trial name
- NCT00698074
- Testing
- Cardiac Resynchronisation Therapy
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University Hospital Birmingham
Hypertrophic Cardiomyopathy
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored…
- Trial name
- NCT06549608
- Testing
- Mavacamten
- Where
- Canada
- Volunteers
- 683 people
- Sponsor
- Bristol-Myers Squibb
Cardiomyopathy, Hypertrophic
Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy
Patients with hypertrophic obstructive cardiomyopathy and New York Heart Association Class I-II under stable treatment with mavacamten (at least 12 weeks without change of dosage) and a peak left ventricular outflow tract…
- Trial name
- MavaEnEx (NCT07077005)
- Testing
- Exercise training
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Technical University of Munich
Fabry Disease
FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation
In Fabry disease (FD) and hypertrophic cardiomyopathy (HCM) systemic inflammation recently gained attention as a possible key pathophysiologic process involved in the development of cardiac hypertrophy and progression of the…
- Trial name
- FASHION (NCT05761834)
- Testing
- Sample blood and 2D-echocardiography with Doppler
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acromegaly Cardiomyopathy
Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
Pathophysiology of acromegaly cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several models of…
- Trial name
- SUM (NCT02611336)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Andrea M. Isidori
Hypertrophic Obstructive Cardiomyopathy
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
Objective of the study: to evaluate whether edge-to-edge technique improves clinical and hemodynamic results in patients scheduled to septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy.
- Trial name
- PRIZMA-pilot (NCT04470102)
- Testing
- mitral valve repair by edge-to-edge technique, Septal myectomy
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Hypertrophic Cardiomyopathy With Obstruction
Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY
This investigation is a prospective, randomized, single-blinded and multicenter design. The purpose of this study is to evaluate the benefit of atrial-synchronous biventricular (BiV) pacing in severely symptomatic hypertrophic…
- Trial name
- TRICHAMPION (NCT01614717)
- Testing
- CRT-P Implant
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Obstructive Hypertrophic Cardiomyopathy
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
The present trial is undertaken as a pilot study on selected patients, to evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of Obstructive Hypertrophic Cardiomyopathy (OHCM)…
- Trial name
- PACE-OHCM (NCT05771987)
- Testing
- pace maker implant guided by acute hemodynamic testing
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Istituto Auxologico Italiano
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
- Trial name
- ACACIA-HCM (NCT06081894)
- Testing
- Aficamten
- Where
- 180 sites in United States, Argentina and 18 more
- Volunteers
- 500 people
- Sponsor
- Cytokinetics